Provided by Tiger Trade Technology Pte. Ltd.

Immix Biopharma, Inc.

12.72
+0.80006.71%
Post-market: 12.750.0300+0.24%19:55 EDT
Volume:1.19M
Turnover:14.82M
Market Cap:905.54M
PE:-14.68
High:12.75
Open:12.24
Low:12.07
Close:11.92
52wk High:15.10
52wk Low:1.94
Shares:71.19M
Float Shares:58.79M
Volume Ratio:0.93
T/O Rate:2.02%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.8667
EPS(LYR):-0.8930
ROE:-34.18%
ROA:-20.52%
PB:3.96
PE(LYR):-14.24

Loading ...

Immix Biopharma, Inc. : Mizuho Raises Target Price to $26 from $15

THOMSON REUTERS
·
Sep 16

U.S. Research Roundup-Domino's, McDonald's, Starbucks

Reuters
·
Sep 16

Immix Biopharma is Maintained at Outperform by Mizuho

Dow Jones
·
Sep 15

Mizuho Raises Price Target on Immix Biopharma to $26 From $15, Keeps Outperform Rating

MT Newswires Live
·
Sep 15

Immix Biopharma Highlights NXC-201 CAR-T Data in Relapsed/refractory AL Amyloidosis Trial Presentation

Reuters
·
Sep 03

Immix Biopharma Price Target Cut to $19.00/Share from $20.00 by Morgan Stanley

Dow Jones
·
Aug 12

Morgan Stanley Adjusts PT on Immix Biopharma to $19 From $20, Maintains Overweight Rating

MT Newswires Live
·
Aug 11

Immix Biopharma Publishes Corporate Presentation on NXC-201 BCMA CAR-T in Relapsed/refractory AL Amyloidosis

Reuters
·
Aug 11

Immix Biopharma is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Aug 10

Analysts Are Bullish on These Healthcare Stocks: Immix Biopharma (IMMX), Ardelyx (ARDX)

TIPRANKS
·
Aug 10

Immix Biopharma, Inc. : H.c. Wainwright Raises Target Price to $25 from $20

THOMSON REUTERS
·
Aug 10

Immix Biopharma, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 08

Immix Biopharma Q2 FY26 Net Loss Widens to USD 11.56 Million; G&A Expense More than Doubled to USD 7.12 Million

Reuters
·
Aug 08

Immix Biopharma, Inc. Expected to Post a Loss of 18 Cents a Share - Earnings Preview

Reuters
·
Aug 05

Immix Biopharma to Attend Morgan Stanley Global Healthcare Conference, Host Investor Meetings

Reuters
·
Aug 04

Immix Biopharma Initiated at Buy by Needham

Dow Jones
·
Jul 22

Needham Initiates Immix Biopharma at Buy With $21 Price Target

MT Newswires Live
·
Jul 22

Immix Biopharma Inc : Needham Initiates Coverage with Buy Rating; Target Price $21

THOMSON REUTERS
·
Jul 22

Immix Biopharma Terminates Richard Graydon Employment

Reuters
·
Jul 20

Immix Biopharma - Richard Graydon Terminated from Immix Biopharma as of July 17, 2026 - SEC Filing

THOMSON REUTERS
·
Jul 20